NCT04322994

THRIVE Use in Pediatric Populations- Multi Site

Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Use in Pediatric Populations: A Randomized Prospective Multi-Site Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 175 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) refers to the use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia. The use of high-flow nasal cannula oxygen supplementation during anesthesia for surgical procedures has been a recent development in the adult population, with limited data analyzing the pediatric population. This study will determine whether high flow nasal cannula oxygen supplementation during surgical or endoscopic procedures can prevent desaturation events in children under anesthesia and improve the outcomes of that surgery.

Conditions

• Oxygen Deficiency
• Desaturation of Blood
• Hypoventilation
• Anesthesia; Adverse Effect

Interventions

Type	Name	Description
DEVICE	Transnasal Humidified Rapid-Insufflation Ventilatory Echange	The use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.

Timeline

• Start date: 2020-10-21
• Primary completion: 2024-01-19
• Completion: 2024-01-19
• First posted: 2020-03-26
• Last updated: 2025-03-27
• Results posted: 2025-03-27

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated device study